Boston Scientific (BSX) Stock Looks Cheap On Earnings But Weak On Execution

Boston Scientific stock has fallen about 56.9% over the past year, yet the valuation checks still lean supportive, which raises the question of whether the share price has moved further than the fundamentals suggest.

• The roughly 56.9% decline over the last 12 months means existing shareholders have taken a heavy hit, while potential new buyers are looking at a much lower entry point.
• The global restructuring plan that targets lower ongoing costs can support valuation over time. However, the execution risk around job cuts and supply chain changes may weigh on how confidently the market prices Boston Scientific.
• On Simply Wall St's broader checks, Boston Scientific screens as attractively priced in 5 out of 6 areas. This points to the stock looking inexpensive on several standard valuation measures, according to its 5 out of 6 value score.

The issue now is whether that weak share price performance reflects a lasting reset in expectations or if the current valuation leaves room for a recovery in Boston Scientific.

Find out why Boston Scientific's -56.9% return over the last year is lagging behind its peers.

Is Boston Scientific Still Cheap on Earnings?

The P/E ratio is a useful way to see how much investors are paying for each dollar of Boston Scientific earnings today. Boston Scientific currently trades on a P/E of 19.2x.

That compares with an industry average P/E of about 29.3x for Medical Equipment and a peer group average near 39.8x. On Simply Wall St's model, a fair P/E for Boston Scientific that reflects its sector, size and risk profile is estimated at 29.3x. This is above the current 19.2x level, which indicates the stock trades at a discount to what this tailored benchmark suggests.

The company is working through a large restructuring that targets lower ongoing costs. The current P/E indicates the market may not be fully pricing in the potential impact that could flow through to earnings if the plan is delivered as outlined.

On this P/E yardstick, Boston Scientific stock appears undervalued compared with both its industry and the modelled fair multiple.

See what the numbers say about this price — find out in our valuation breakdown.

The Boston Scientific Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Boston Scientific sit on the Community page and act as the missing link between the current P/E discount and the assumptions that would need to hold on growth, margins and earnings for the stock to be worth materially more or less than today. Each Narrative ties a fair value estimate to a specific storyline about Boston Scientific's possible catalysts and risks, allowing you to later compare which version of events seems to be unfolding.

One of the top community narratives on Boston Scientific: 53% undervalued

"The immediate impact of the Penumbra acquisition has been somewhat heavy on the stock’s valuation for a few key reasons..."

Read one of the top narratives on Boston Scientific

Do you think there's more to the story for Boston Scientific? Head over to our Community to see what others are saying!

The Bottom Line

Boston Scientific screens as undervalued on current market multiples, which reflects a gap between what investors are paying today and what peers in the same industry trade on. The crux is whether the restructuring plan actually delivers the cost savings and margin profile that would support those higher peer multiples. If execution on job cuts and supply chain changes proves smooth, the current discount could look appealing. If setbacks emerge or the benefits are slower or smaller than hoped, the lower P/E may simply be the market correctly pricing ongoing execution risk.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com